


The Value of

IMPACT[®]
**Advanced
Recovery**

IMPACT[®]* helps support the nutritional management of patients undergoing major elective surgery at risk of infection



**META-ANALYSES IN MAJOR ELECTIVE SURGERY
INDICATED THAT NUTRITIONAL MANAGEMENT WITH IMPACT[®]*,**



**REDUCES
RISK OF POSTOPERATIVE
INFECTIONS**

by 51% versus
standard of care (SOC)
($p < 0.00001$)¹⁻⁵



**REDUCES
RATE OF DIFFERENT TYPES
OF INFECTIONS**

from wound infections
(37%) to abdominal abscesses
(54%) compared with
control products⁶



**REDUCES
LOS BY > 2 DAYS
VERSUS SOC**
($p < 0.00001$ ¹; $p < 0.001$ ²)

**MAJOR NUTRITION GUIDELINES (ESPEN CLINICAL GUIDELINES)
RECOGNISE THE BENEFIT AND RECOMMEND THE USE OF
IMMUNOMODULATING NUTRITIONAL SUPPLEMENTS**

for malnourished patients in surgery (ESPEN),⁷ and oncology patients (ESPEN)⁸

DUE TO THE PHYSIOLOGICAL RESPONSES TO THE STRESS OF MAJOR ELECTIVE SURGERY,
APPROXIMATELY 11%
OF PATIENTS DEVELOP INFECTIONS,⁹
OF WHICH 22% ARE SURGICAL SITE INFECTIONS¹⁰ AND
UP TO 13.5% ARE GASTROINTESTINAL ANASTOMOTIC LEAKS¹¹



INFECTIONS

In gastric cancer surgery, **RATES OF 26.7% FOR WOUND HEALING COMPLICATIONS¹², 20% FOR INFECTIONS¹² AND 7.3% FOR ANASTOMOTIC LEAKS¹³** are reported for patients receiving standard postoperative enteral nutrition

Numerous meta-analyses showed **HIGHER RATES OF POSTOPERATIVE SURGICAL SITE INFECTIONS, LOS AND ANASTOMOTIC LEAKS** with standard nutritional support compared with immunomodulating products including IMPACT®*^{3,6,14}

Preoperative immunonutrition in patients undergoing surgery for gastrointestinal cancer **REDUCED THE INCIDENCE RATES OF INFECTIOUS COMPLICATIONS** (18.6% in the immunonutrition group compared with 29.31% $P < 0.0001$) when compared with control (isocaloric isonitrogenous feed or normal diet)¹⁵



POSTOPERATIVE COMPLICATIONS COULD ADVERSELY AFFECT RECOVERY OF PATIENTS UNDERGOING MAJOR ELECTIVE SURGERY



POSTOPERATIVE COMPLICATIONS INCREASE LENGTH OF STAY
by approximately 2-fold across surgeries^{11,16,17}



POSTOPERATIVE COMPLICATIONS ADVERSELY AFFECT PATIENT MORTALITY:

- Postoperative infections in patients after elective surgery increase mortality (0.8% vs 0.3%; $p < 0.01$) compared with patients without infection in the 30-day period after surgery¹⁸
- Anastomotic leaks after gastrointestinal surgery result in greater 30-day mortality (8.4% vs 2.5%, $p < 0.0001$) and long-term mortality (36.4% vs 20.0%; $p < 0.0001$) compared with patients with intact anastomoses¹¹



Patients with postoperative complications are **1.3 TIMES¹⁹ TO ALMOST 5 TIMES MORE LIKELY TO BE READMITTED TO HOSPITAL** when compared with patients without complications⁹



Postoperative **COMPLICATIONS INCREASE HEALTHCARE COSTS** by 29% in general elective surgery⁹ and up to 62% in cancer surgery^{16-18,20}



POSTOPERATIVE COMPLICATIONS REDUCE PATIENT QUALITY OF LIFE²¹⁻²³

BY REDUCING POSTOPERATIVE COMPLICATIONS,²⁰ READMISSIONS,^{20,24} AND LOS,²⁰ IMMUNONUTRITION COULD RESULT IN SUBSTANTIAL HEALTHCARE COST SAVINGS* COMPARED WITH SOC

A cost-effectiveness[†] analysis revealed that immunonutrition produced **SAVINGS PER PATIENT OF 31%** when administered perioperatively, 28% (preoperatively) and 22% (postoperatively) in gastrointestinal cancer surgery patients when compared with SOC²⁰



IMPACT® ADVANCED RECOVERY IS AN IMMUNOMODULATING ORAL NUTRITIONAL SUPPLEMENT

containing dietary nucleotides, arginine, and omega-3 fatty acids



ORDERING INFORMATION

SKU	Presentation	Units Per Case	Product Code
IMPACT® Advanced Recovery	250mL Tetra Prisma®	10 x 250mL	12497527

ESPEN: The European Society for Clinical Nutrition and Metabolism; LOS: Length of stay; SOC: Standard of care.

*The evidence in this document comes from both Oral IMPACT® and IMPACT® Advanced Recovery, both of which contain the immunonutrients – arginine, omega-3 fish oil and dietary nucleotides. IMPACT® Advanced Recovery contains higher amounts of arginine and omega-3 fish oil than Oral IMPACT®, however nucleotides in IMPACT® Advanced Recovery may be higher or lower than Oral IMPACT® that has been used in the clinical studies depending on the recipe of the product at the time. IMPACT® Advanced Recovery is the product that is available in Australia.

†Cost savings data displayed are derived from the referenced study sponsored by Nestlé Health Science. Every facility is different and actual cost savings may vary. Other factors may also impact on costs. Nestlé Health Science does not make any representation or warranty regarding actual or potential cost savings.

REFERENCES

1. Drover JW, *et al.* J Am Coll Surg, 2011.
2. Marik PE, *et al.* J Parenter Enteral Nutr, 2010.
3. Cerantola Y, *et al.* Br J Surg, 2011.
4. Buzquurz F, *et al.* BJS Open, 2020.
5. Mazaki T, *et al.* Ann Surg, 2015.
6. Waitzberg DL, *et al.* World J Surg, 2006.
7. Weimann A, *et al.* Clinical Nutrition, 2021.
8. Arends J, *et al.* Clinical Nutrition, 2017.
9. Berger A, *et al.* Surg Infect (Larchmt), 2014.
10. Magill SS, *et al.* N Engl J Med, 2014.
11. Turrentine FE, *et al.* J Am Coll Surg, 2015.
12. Farreras N, *et al.* Clin Nutr, 2005.
13. Marano L, *et al.* Ann Surg Oncol, 2013.
14. Marimuthu K, *et al.* Ann Surg, 2012.
15. Adiamah A, *et al.* Ann Surg, 2019.
16. Lang M, *et al.* Br J Surg, 2001.
17. Thompson DA, *et al.* Ann Surg, 2006.
18. Mauskopf JA, *et al.* World J Surg Oncol, 2012.
19. Hammond J, *et al.* J Gastrointest Surg, 2014.
20. Chevrou-Severac H *et al.* Clin Nutr, 2013.
21. Bouras G, *et al.* Ann Surg, 2014.
22. Whitehouse JD, *et al.* Infect Control Hosp Epidemiol, 2002.
23. Perencevich EN, *et al.* Emerg Infect Dis, 2003.
24. Benerjee S, *et al.* Nutr. 2017.

IMPACT® Advanced Recovery is a food for special medical purposes specifically formulated for medical conditions where nutritional needs cannot be met by diet modification alone. Must be used under the supervision of a healthcare professional.

Tetra Pak® and Tetra Prisma® are trademarks of AB Tetra Pak, Ruben Rausing's gata, 221 86, Lund, Sweden. Telephone: +46 46 36 10 00, www.tetrapak.com

© Reg. Trademark of Société des Produits Nestlé S.A. Nestlé Healthcare Nutrition, a division of Nestlé Australia Ltd, 8 Nexus Court, Mulgrave VIC 3170, Australia. For more information call 1800 671 628 or visit www.nestlehealthscience.com.au

Information for healthcare professional use only.

Date of preparation: June 2022

